The Catalyst

Most Recent Posts

03.06.14 | By Matt Bennett

Since taking effect in 2006, Medicare Part D has provided seniors with critical access to the prescription medications they need. As part of the program, patients have broader access to medicines that fall into one of six “protected classes” that include anticonvulsants, antidepressants, antineoplastics, antipsychotics, antiretrovirals and immunosuppressants.

03.06.14 | By Randy Burkholder

This post originally appeared on the Age of Personalized Medicine.

03.06.14 | By Stephanie Fischer

Since the Accelerating Medicines Partnership (AMP) was announced last month, there’s been robust discussion throughout the scientific community and the general public about the goals of this unique partnership between the National Institutes of Health (NIH), several non-profit disease foundations, 10 biopharmaceutical compani

03.05.14 | By John Castellani

Patients, physicians, biopharmaceutical companies, and the federal government all want the same thing: New treatment options to save lives from diseases that claim far too many.

CBS This Morning
03.03.14 | By Jenni Brewer

The Sunshine Act encourages transparency around the interactions between physicians and biopharmaceutical professionals. These conversations are vital to improving patient care.

02.28.14 | By Kaelan Hollon

We revisit the research and development (R&D) pipeline quite a bit, because it is a crucially important aspect of modern medicine. Having recently released our Medicines in Development report on the 180 medicines in the pipeline to treat diabetes and related conditions, it is important to recognize the steps that fuel innovation and medical advances.

02.27.14 | By John Castellani

By 2020, nearly half of all Americans will have at least one chronic condition. As more and more people are afflicted by chronic disease, it is increasingly important to develop new ways to prevent, manage, and treat these life-altering conditions.

02.26.14 | By Matt Bennett

The existing model of bringing new medicines to patients is a costly, exhaustive, and thorough process. In fact, to develop a new medicine under the federal process takes about $1 billion and 10 years — with a failure rate of roughly 99 percent.

02.26.14 | By Stephanie Fischer

Developing new medicines is a lengthy and complex process, relying heavily on volunteer participation to evaluate potential therapies for safety and effectiveness in clinical trials. Without the patients who volunteer to participate in clinical research, the development of new treatments would not be possible.

Challenges in Patient Recruitment

02.24.14 | By Jay Taylor

Today, I had the opportunity to offer PhRMA’s perspective on inadequate intellectual property (IP) rights and other major trade barriers around the world during the U.S.

02.21.14 | By Kaelan Hollon

Despite the inevitable hurdles and roadblocks that arise throughout the R&D process, this past week we highlighted the medical breakthroughs aimed to improve the lives of patients around the world.

02.21.14 | By Jenni Brewer

CMS recently released a proposed rule that would significantly change Part D, the prescription drug program in Medicare, potentially jeopardizing coverage, choice, access and affordability for beneficiaries. In a Feb.

02.20.14 | By Jeff Francer

A new book, the Cure in the Code: How 20th Century Law is Undermining 21st Century Medicine, provides a fascinating overview of advances in biomedical science with the potential to revolutionize how diseases are treated by providing patients with more targeted therapies.

02.17.14 | By Mark Grayson

At the International Trade Commission (ITC) hearing on the investigation into India's trade policies, Rod Hunter, PhRMA’s Senior Vice President for International Affairs, highlighted the industry's concerns and hopes surrounding India’s policies.

NORD President and CEO Peter Saltonstall
02.17.14 | By Stephanie Fischer

Many biopharmaceutical companies are actively engaged in the research and development of therapies to treat rare disease, despite challenges such as much smaller patient populations than more common diseases. Companies seek opportunities to partner with patient advocacy organizations, academia and the government in order to make even greater progress against rare disease, which collectively affect 1 in 10 Americans.

Pages